Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes
Low-dose interleukin-2 is showing promise in the treatment of several autoimmune inflammatory diseases. Here authors map the trajectory of cellular and transcriptional changes in type 1 diabetes patients receiving an interval dosing interleukin-2 regimen, which shows an anti-inflammatory gene expres...
Main Authors: | Jia-Yuan Zhang, Fiona Hamey, Dominik Trzupek, Marius Mickunas, Mercede Lee, Leila Godfrey, Jennie H. M. Yang, Marcin L. Pekalski, Jane Kennet, Frank Waldron-Lynch, Mark L. Evans, Timothy I. M. Tree, Linda S. Wicker, John A. Todd, Ricardo C. Ferreira |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-11-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-34162-3 |
Similar Items
-
Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes
by: Zhang, J-Y, et al.
Published: (2022) -
Single-cell multi-omics analysis reveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus erythematosus [version 1; peer review: 1 approved, 2 approved with reservations]
by: Dominik Trzupek, et al.
Published: (2021-06-01) -
In-depth immunophenotyping data of IL-6R on the human peripheral regulatory T cell (Treg) compartment
by: Ferreira, R, et al.
Published: (2017) -
In-depth immunophenotyping data of IL-6R on the human peripheral regulatory T cell (Treg) compartment.
by: Ferreira, R, et al.
Published: (2017) -
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes
by: Seelig, E, et al.
Published: (2018)